All questions are shown as received by the Trust.
Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.
1. How many newly diagnosed patients with chronic lymphocytic leukaemia (CLL) have started first-line treatment in your Trust or Centre during the 6-month period February 2024 to July 2024?
2. How many of these newly diagnosed patients with CLL received chemoimmunotherapy (CIT) as first-line treatment?
CITs include fludarabine + cyclophosphamide + rituximab (FCR), fludarabine + rituximab (FR), bendamustine + rituximab (BR), bendamustine monotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), obinutuzumab ± chlorambucil, rituximab + chlorambucil and ofatumumab
3. Please complete the table below with how many newly diagnosed patients with CLL have started first-line treatment with each of the following CITs during the 6-month period February 2024 to July 2024
a. FCR (fludarabine + cyclophosphamide + rituximab)
b. FR (fludarabine + rituximab)
c. BR (bendamustine + rituximab)
d. Bendamustine monotherapy
e. RCHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)
f. Obinutuzumab ± chlorambucil
g. Rituximab + chlorambucil
h. Ofatumumab
i. Other – please specify
Note: this should only include newly diagnosed patients with CLL who have started first-line treatment during the 6-month window